Loading...
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
Na minha lista:
| Udgivet i: | Clin Kidney J |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://ncbi.nlm.nih.gov/pubmed/34221378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfab062 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|